Matching articles for "Proventil"
Issue 1716 · November 25, 2024
Drugs for Asthma

The goal of asthma treatment is to control symptoms, prevent exacerbations, and maintain normal lung function. Management of acute exacerbations in the emergency department is not discussed here.

Med Lett Drugs Ther. 2024 Nov 25; 66(1716):185-92 doi:10.58347/tml.2024.1716a
The goal of asthma treatment is to control symptoms, prevent exacerbations, and maintain normal lung function. Management of acute exacerbations in the emergency department is not discussed here.
Issue 1716 · November 25, 2024
Comparison Chart: Correct Use of Inhalers for Asthma (online only)

View the Comparison Chart: Correct Use of Inhalers for Asthma

Med Lett Drugs Ther. 2024 Nov 25; 66(1716):e196-8 doi:10.58347/tml.2024.1716c
View the Comparison Chart: Correct Use of Inhalers for Asthma
Issue 1698 · March 18, 2024 Free
Airsupra: An Inhaled Albuterol/Budesonide Combination for Asthma

The FDA has approved Airsupra (AstraZeneca), a metered-dose inhaler containing the short-acting beta 2 -agonist (SABA) albuterol and the inhaled corticosteroid (ICS) budesonide, for use as needed for treatment…

Med Lett Drugs Ther. 2024 Mar 18; 66(1698):41-3 doi:10.58347/tml.2024.1698a
The FDA has approved Airsupra (AstraZeneca), a metered-dose inhaler containing the short-acting beta 2 -agonist (SABA) albuterol and the inhaled corticosteroid (ICS) budesonide, for use as needed for treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients ≥18 years old with asthma. Airsupra is the first combination of a SABA and an ICS to become available in the US. It is not approved for use as maintenance therapy.
Issue 1613 · December 14, 2020
Drugs for Asthma

The goal of asthma treatment is to control symptoms, prevent exacerbations, and maintain normal lung function. Management of acute exacerbations of asthma in the emergency department is not discussed here.

Med Lett Drugs Ther. 2020 Dec 14; 62(1613):193-200
The goal of asthma treatment is to control symptoms, prevent exacerbations, and maintain normal lung function. Management of acute exacerbations of asthma in the emergency department is not discussed here.
Issue 1613 · December 14, 2020
Table: Some Inhaled Drugs for Treatment of Asthma (online only)

View the table: Some Inhaled Drugs for Treatment of Asthma

Med Lett Drugs Ther. 2020 Dec 14; 62(1613):e200-3
View the table: Some Inhaled Drugs for Treatment of Asthma
Issue 1606 · September 7, 2020
Drugs for COPD

The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Several guidelines and…

Med Lett Drugs Ther. 2020 Sep 7; 62(1606):137-44
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Several guidelines and review articles on COPD treatment have been published in recent years. Treatment of acute exacerbations is not discussed here.
Issue 1606 · September 7, 2020
Table: Correct Use of Inhalers for COPD (online only)

View the Table: Correct Use of Inhalers for COPD

Med Lett Drugs Ther. 2020 Sep 7; 62(1606):e150-4
View the Table: Correct Use of Inhalers for COPD
Issue 1606 · September 7, 2020
Comparison Table: Inhaled Short-Acting Bronchodilators for Treatment of COPD (online only)

View the Comparison Table: Inhaled Short-Acting Bronchodilators for Treatment of COPD

Med Lett Drugs Ther. 2020 Sep 7; 62(1606):e144-5
View the Comparison Table: Inhaled Short-Acting Bronchodilators for Treatment of COPD
Issue 1564 · January 28, 2019
OTC Primatene Mist Returns

The FDA has approved over-the-counter (OTC) sale of inhaled epinephrine ( Primatene Mist – Amphastar), a nonselective alpha and beta agonist, for temporary relief of mild symptoms of intermittent asthma in…

Med Lett Drugs Ther. 2019 Jan 28; 61(1564):9-10
The FDA has approved over-the-counter (OTC) sale of inhaled epinephrine ( Primatene Mist – Amphastar), a nonselective alpha and beta agonist, for temporary relief of mild symptoms of intermittent asthma in patients ≥12 years old who have been diagnosed with mild intermittent asthma by a healthcare professional. The original version of Primatene Mist , which was approved by the FDA in 1967, was removed from the market in 2011 because the metered-dose inhaler (MDI) contained ozone-depleting chlorofluorocarbon (CFC) propellants; the new MDI contains hydrofluoroalkane (HFA) propellants.
Issue 1562 · December 17, 2018 Free
Drugs for Cough

Acute cough (<3 weeks in duration) generally does not require pharmacologic treatment, especially in children. Suppression of productive cough may be harmful. Management of patients with cough should include…

Med Lett Drugs Ther. 2018 Dec 17; 60(1562):206-8
Acute cough (<3 weeks in duration) generally does not require pharmacologic treatment, especially in children. Suppression of productive cough may be harmful. Management of patients with cough should include elimination of any precipitating factor (e.g., cigarette smoking) and treatment of any underlying cause such as upper airway cough syndrome, gastroesophageal reflux disease, asthma, or other pulmonary disease.
Issue 1528 · August 28, 2017
Drugs for Asthma

The goal of asthma treatment is to control symptoms and prevent exacerbations. Management of acute exacerbations of asthma is not discussed here.

Med Lett Drugs Ther. 2017 Aug 28; 59(1528):139-46
The goal of asthma treatment is to control symptoms and prevent exacerbations. Management of acute exacerbations of asthma is not discussed here.
Issue 1528 · August 28, 2017
Comparison Table: Some Inhaled Drugs for Treatment of Asthma (online only)

View the Comparison Table: Some Inhaled Drugs for Treatment of Asthma

Med Lett Drugs Ther. 2017 Aug 28; 59(1528):e146-9
View the Comparison Table: Some Inhaled Drugs for Treatment of Asthma
Issue 1528 · August 28, 2017
Comparison Table: Correct Use of Inhalers for Asthma (online only)

View the Comparison Table: Correct Use of Inhalers

Med Lett Drugs Ther. 2017 Aug 28; 59(1528):e150-2
View the Comparison Table: Correct Use of Inhalers
Issue 1518 · April 10, 2017
Comparison Table: Inhaled Short-Acting Bronchodilators for COPD (online only)

View the Comparison Table: Inhaled Short-Acting Bronchodilators for COPD

Med Lett Drugs Ther. 2017 Apr 10; 59(1518):e62-3
View the Comparison Table: Inhaled Short-Acting Bronchodilators for COPD
Issue 1518 · April 10, 2017
Drugs for COPD

The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Updated guidelines for…

Med Lett Drugs Ther. 2017 Apr 10; 59(1518):57-62
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Updated guidelines for treatment of COPD have been published in recent years.
Issue 1518 · April 10, 2017
Table: Correct Use of Inhalers for COPD (online only)

View the Table: Correct Use of Inhalers for COPD

Med Lett Drugs Ther. 2017 Apr 10; 59(1518):e67-71
View the Table: Correct Use of Inhalers for COPD
Issue 1480 · October 26, 2015 Free
In Brief: A New Albuterol Inhaler (ProAir RespiClick) for Asthma

The short-acting beta 2 -agonist albuterol sulfate is now available as a dry powder for inhalation ( ProAir RespiClick – Teva) for prevention and treatment of broncho spasm in patients ≥12 years old.…

Med Lett Drugs Ther. 2015 Oct 26; 57(1480):150
The short-acting beta 2 -agonist albuterol sulfate is now available as a dry powder for inhalation ( ProAir RespiClick – Teva) for prevention and treatment of broncho spasm in patients ≥12 years old. ProAir RespiClick is the only short-acting beta 2 -agonist dry powder inhaler available in the US. Metered-dose inhalers (MDIs) use a hydrofluoroalkane (HFA) propellant. They require coordination of inhalation with actuation; using them with a valved holding chamber minimizes this need, but decreases portability because of the size of the chamber. Dry powder inhalers such as ProAir RespiClick , which are breath-actuated, do not require a propellant and do not have to be primed before use. They do not require coordination of inhalation with actuation, but patients must be capable of performing a rapid, deep inhalation, which might be difficult during a severe asthma attack. The recommended dose of ProAir RespiClick for treatment of bronchospasm is 2 inhalations, but 1 inhalation may be sufficient for some patients. The dose can be repeated every 4-6 hours as needed. For prevention of exercise-induced bronchospasm, the recommended dosage is 2 inhalations 15-30 minutes before exercise. Each ProAir RespiClick inhaler includes a dose counter. Opening the mouthpiece cap readies a dose for administration and causes the counter to count down by 1; closing the cap without inhaling the medication wastes that dose. The inhaler should be cleaned with a dry cloth as needed. ProAir RespiClick may contain trace levels of milk proteins; it is contraindicated for use in patients with a history of a severe hypersensitivity reaction to milk proteins. Download complete U.S. English article
Issue 132 · August 1, 2013
Drugs for Asthma and COPD

INHALATION DEVICES — Metered-dose inhalers (MDIs) require coordination of inhalation with hand-actuation of the device. Valved holding chambers (VHCs) or spacers help some patients, especially young children…

Treat Guidel Med Lett. 2013 Aug; 11(132):75-86
INHALATION DEVICES — Metered-dose inhalers (MDIs) require coordination of inhalation with hand-actuation of the device. Valved holding chambers (VHCs) or spacers help some patients, especially young children and the elderly, use MDIs effectively. VHCs have one-way valves that prevent the patient from exhaling into the device, minimizing the need for coordinated actuation and inhalation. Spacers are tubes or chambers placed between the canister and a face mask or mouthpiece, which also avoids the need to coordinate actuation and inhalation. Both VHCs and spacers retain the larger particles emitted from the MDI, decreasing their deposition in the oropharynx and leading to a higher proportion of small respirable particles being inhaled.
Issue 114 · February 1, 2012
Drugs for Asthma

Inhalation is the preferred route of delivery for most asthma drugs. Chlorofluorocarbons (CFCs), which have ozone-depleting properties, are being phased out as propellants in metered-dose inhalers.…

Treat Guidel Med Lett. 2012 Feb; 10(114):11-8
Inhalation is the preferred route of delivery for most asthma drugs. Chlorofluorocarbons (CFCs), which have ozone-depleting properties, are being phased out as propellants in metered-dose inhalers. Non-chlorinated hydrofluoroalkane (HFA) propellants, which do not deplete the ozone layer, are being used instead.
Issue 99 · November 1, 2010
Drugs for Chronic Obstructive Pulmonary Disease

The goals of drug therapy for chronic obstructive pulmonary disease (COPD) are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and decrease complications of the disease such…

Treat Guidel Med Lett. 2010 Nov; 8(99):83-8
The goals of drug therapy for chronic obstructive pulmonary disease (COPD) are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and decrease complications of the disease such as acute exacerbations. Other guidelines for treatment of this condition have been published or updated in recent years.
Issue 1339 · May 31, 2010
Safety of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease (COPD)

Two combinations of an inhaled corticosteroid with an inhaled long-acting beta2-agonist are approved by the FDA for use in patients with COPD: fluticasone/salmeterol (Advair Diskus) and budesonide/formoterol…

Med Lett Drugs Ther. 2010 May 31; 52(1339):41-2
Two combinations of an inhaled corticosteroid with an inhaled long-acting beta2-agonist are approved by the FDA for use in patients with COPD: fluticasone/salmeterol (Advair Diskus) and budesonide/formoterol (Symbicort) . A Medical Letter reader has questioned the safety of using corticosteroid inhalers in patients with this disorder. No single-agent inhaled corticosteroid inhaler is approved for this indication.
Issue 76 · December 1, 2008
Drugs for Asthma

No truly new drugs have been approved for treatment of asthma since omalizumab (Xolair) in 2003, but some randomized controlled trials of older drugs have been published, and new guidelines have become…

Treat Guidel Med Lett. 2008 Dec; 6(76):83-90
No truly new drugs have been approved for treatment of asthma since omalizumab (Xolair) in 2003, but some randomized controlled trials of older drugs have been published, and new guidelines have become available.
Issue 1298 · November 3, 2008 Free
In Brief: New Propellants for Albuterol Metered-Dose Inhalers

Inhaled drugs for asthma are available in the US mainly in pressurized metered-dose inhalers (MDIs), which require a propellant, and dry powder inhalers, which do not. The chlorofluorocarbon (CFC) propellants…

Med Lett Drugs Ther. 2008 Nov 3; 50(1298):85
Inhaled drugs for asthma are available in the US mainly in pressurized metered-dose inhalers (MDIs), which require a propellant, and dry powder inhalers, which do not. The chlorofluorocarbon (CFC) propellants in MDIs are being replaced by hydrofluoroalkane (HFA) propellants for environmental reasons: CFCs contribute to the depletion of the ozone layer. December 31, 2008 will be the last day that albuterol MDIs using CFC propellants can be sold in the US. The FDA is expected to announce a termination date for other CFC-containing products in the near future. Three HFA albuterol inhalers and one HFA levalbuterol inhaler have been approved by the FDA. None is available generically. HFA inhalers require priming — firing 4 puffs into the air (3 with ProAir ) — the first time they are used, and after 2 weeks of non-use (3 days with Xopenex HFA ). In general, HFA sprays taste different, are less forceful, and are warmer and mistier than CFC sprays. Some patients may have to be reassured that they are getting enough of their medication, but actually the smaller particles of the HFA sprays may reach the lungs more readily than CFC sprays. Download U.S. English
Issue 63 · November 1, 2007
Drugs for Chronic Obstructive Pulmonary Disease

The goals of drug therapy for chronic obstructive pulmonary disease (COPD) are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and minimize complications of the disease such…

Treat Guidel Med Lett. 2007 Nov; 5(63):95-100
The goals of drug therapy for chronic obstructive pulmonary disease (COPD) are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and minimize complications of the disease such as acute exacerbations and cor pulmonale. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines developed by the World Health Organization and the National Heart, Lung and Blood Institute were updated in 2006. The American Thoracic Society and the European Respiratory Society jointly developed guidelines for COPD in 2004.
Issue 33 · May 1, 2005
Drugs for Asthma

Patients with mild, infrequent asthma symptoms may require only intermittent, asneeded use of an inhaled short-acting beta2-adrenergic agonist. Use of a short-acting beta2-agonist more than twice weekly, other…

Treat Guidel Med Lett. 2005 May; 3(33):33-8
Patients with mild, infrequent asthma symptoms may require only intermittent, asneeded use of an inhaled short-acting beta2-adrenergic agonist. Use of a short-acting beta2-agonist more than twice weekly, other than for exercise-induced bronchospasm, indicates a need for anti-inflammatory treatment. Inhaled corticosteroids are the most effective anti-inflammatory medication; leukotriene modifiers are less effective alternatives. If regular use of an inhaled corticosteroid in a low dose does not prevent symptoms, a long-acting beta2-agonist should be added; addition of a second drug is more effective than raising the dose of the inhaled steroid. A leukotriene modifier can also be used as the second drug. Omalizumab may be considered as adjunctive therapy for patients more than 12 years old who have allergic asthma not controlled by other drugs. A short course of oral corticosteroids may be useful for acute exacerbations. Treatment of acute severe asthma as a medical emergency is not included here; it has been reviewed elsewhere (ER McFadden Jr, Am J Respir Crit Care Med 2003; 168:740) .
Issue 1159 · June 23, 2003
Prilosec, Nexium and Stereoisomers

Recently pharmaceutical manufacturers have marketed a stereoisomer of a successful drug nearing patent expiration as a new drug. Examples, such as esomeprazole (Nexium) , levalbuterol (Xopenex), escitalopram…

Med Lett Drugs Ther. 2003 Jun 23; 45(1159):51-2
Recently pharmaceutical manufacturers have marketed a stereoisomer of a successful drug nearing patent expiration as a new drug. Examples, such as esomeprazole (Nexium) , levalbuterol (Xopenex), escitalopram (Lexapro) and dexmethylphenidate
Issue 2 · October 1, 2002
Drugs for Asthma

New drug formulations continue to be introduced for the treatment of asthma, and new studies on older drugs continue to change our perspectives on the management of this chronic inflammatory disease. Treatment…

Treat Guidel Med Lett. 2002 Oct; 0(2):7-12
New drug formulations continue to be introduced for the treatment of asthma, and new studies on older drugs continue to change our perspectives on the management of this chronic inflammatory disease. Treatment of asthma in the emergency department or hospital is not addressed here. More information on the diagnosis and treatment of asthma is available from Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma (Bethesda:NIH, 1997 and 2002 update; www.nhlbi.nih.gov ).
Issue 1121 · January 7, 2002
Prevention and Treatment of Injury from Chemical Warfare Agents

The recent terrorist attacks on the US have led to many questions about the clinical effects, prevention and treatment of injury caused by chemical warfare agents.

Med Lett Drugs Ther. 2002 Jan 7; 44(1121):1-4
The recent terrorist attacks on the US have led to many questions about the clinical effects, prevention and treatment of injury caused by chemical warfare agents.
Issue 1104 · May 14, 2001
Formoterol (Foradil Aerolizer) For Asthma

Formoterol fumarate inhalation powder Foradil Aerolizer , a long-acting beta2-adrenergic receptor agonist, has been approved by the FDA for maintenance treatment of asthma and prevention of exercise-induced…

Med Lett Drugs Ther. 2001 May 14; 43(1104):39-40
Formoterol fumarate inhalation powder Foradil Aerolizer , a long-acting beta2-adrenergic receptor agonist, has been approved by the FDA for maintenance treatment of asthma and prevention of exercise-induced bronchospasm. The drug has been available in Europe for many years.
Issue 1102 · April 16, 2001
A Combination of Fluticasone and Salmeterol For Asthma

Fluticasone propionate, an inhaled corticosteroid, and salmeterol xinafoate, a long-acting beta2-adrenergic agonist, are now available together in a dry-powder inhaler for maintenance treatment of patients…

Med Lett Drugs Ther. 2001 Apr 16; 43(1102):31-3
Fluticasone propionate, an inhaled corticosteroid, and salmeterol xinafoate, a long-acting beta2-adrenergic agonist, are now available together in a dry-powder inhaler for maintenance treatment of patients with asthma. The new combination is not recommended for treatment of acute bronchospasm or for treatment of children less than 12 years old.
Issue 1073 · March 6, 2000
Drugs for Asthma

Asthma is a chronic inflammatory disorder of the airways; inflammation caused by allergens, viral respiratory infections or other stimuli leads to bronchial hyperresponsiveness and obstruction of airflow.…

Med Lett Drugs Ther. 2000 Mar 6; 42(1073):19-24
Asthma is a chronic inflammatory disorder of the airways; inflammation caused by allergens, viral respiratory infections or other stimuli leads to bronchial hyperresponsiveness and obstruction of airflow. Anti-inflammatory drugs, particularly inhaled corticosteroids, are central to its management.
Issue 1054 · June 4, 1999
Levalbuterol for Asthma

Levalbuterol, the R-isomer of racemic albuterol, has been approved by the FDA for prevention and treatment of bronchospasm in patients at least 12 years old.

Med Lett Drugs Ther. 1999 Jun 4; 41(1054):51-3
Levalbuterol, the R-isomer of racemic albuterol, has been approved by the FDA for prevention and treatment of bronchospasm in patients at least 12 years old.
Issue 1044 · January 15, 1999
Drugs for Asthma

Asthma is a chronic inflammatory disorder, with inflammation caused by allergens or other stimuli leading to bronchial hyperresponsiveness and obstruction of airflow.

Med Lett Drugs Ther. 1999 Jan 15; 41(1044):5-10
Asthma is a chronic inflammatory disorder, with inflammation caused by allergens or other stimuli leading to bronchial hyperresponsiveness and obstruction of airflow.
Issue 921 · April 29, 1994
Salmeterol

Salmeterol xinafoate ( Serevent - Allen & Hanburys), a long-acting β 2 -selective adrenergic agonist for inhalation, has been approved by the US Food and Drug Administration for maintenance treatment of…

Med Lett Drugs Ther. 1994 Apr 29; 36(921):37-8
Salmeterol xinafoate ( Serevent - Allen & Hanburys), a long-acting β 2 -selective adrenergic agonist for inhalation, has been approved by the US Food and Drug Administration for maintenance treatment of asthma, with or without concurrent use of inhaled corticosteroids. Salmeterol is not recommended for acute treatment of bronchospasm.